Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MIRM 
Mirum Pharmaceuticals Inc (MIRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/10/2025: MIRM (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $85.81
1 Year Target Price $85.81
| 6 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 54.24% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/10/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.50B USD | Price to earnings Ratio - | 1Y Target Price 85.81 |
Price to earnings Ratio - | 1Y Target Price 85.81 | ||
Volume (30-day avg) 10 | Beta 0.42 | 52 Weeks Range 36.88 - 78.54 | Updated Date 11/9/2025 |
52 Weeks Range 36.88 - 78.54 | Updated Date 11/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.1462 | Actual 0.05 |
Profitability
Profit Margin -8.78% | Operating Margin (TTM) 1.96% |
Management Effectiveness
Return on Assets (TTM) -3.6% | Return on Equity (TTM) -15.81% |
Valuation
Trailing PE - | Forward PE 39.68 | Enterprise Value 3618897172 | Price to Sales(TTM) 7.42 |
Enterprise Value 3618897172 | Price to Sales(TTM) 7.42 | ||
Enterprise Value to Revenue 8.43 | Enterprise Value to EBITDA -8.85 | Shares Outstanding 51393574 | Shares Floating 41132847 |
Shares Outstanding 51393574 | Shares Floating 41132847 | ||
Percent Insiders 1.84 | Percent Institutions 111.12 |
Upturn AI SWOT
Mirum Pharmaceuticals Inc
Company Overview
History and Background
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for debilitating liver diseases. It was founded in 2011 as Tobira Therapeutics spinoff. Key milestones include the approvals of LIVMARLI for cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC).
Core Business Areas
- Drug Development and Commercialization: Focuses on developing and commercializing therapies for rare and orphan liver diseases.
- LIVMARLI: Commercialization and life cycle management of LIVMARLI (maralixibat) oral solution.
Leadership and Structure
Chris Peetz is the current CEO. The organizational structure includes departments focused on research and development, clinical operations, commercialization, and finance.
Top Products and Market Share
Key Offerings
- LIVMARLI (maralixibat): LIVMARLI is approved for cholestatic pruritus associated with Alagille syndrome and for the treatment of progressive familial intrahepatic cholestasis (PFIC). Market share and revenue figures for LIVMARLI are tracked in company financial reports. Competitors for Alagille Syndrome symptoms are off-label treatments. Competitors for PFIC include gene therapy development companies.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on rare liver diseases is a specialized and growing market. There is a high unmet need for effective treatments.
Positioning
Mirum is positioned as a leader in developing therapies for rare liver diseases, particularly cholestatic conditions. Its competitive advantage lies in its approved therapy and pipeline of novel treatments.
Total Addressable Market (TAM)
The TAM for rare liver diseases is estimated to be in the billions of dollars. Mirum is positioned to capture a significant share of this market with its approved therapies and pipeline.
Upturn SWOT Analysis
Strengths
- Approved Therapy (LIVMARLI)
- Strong Pipeline in Rare Liver Diseases
- Experienced Management Team
- Orphan Drug Designation for Key Products
Weaknesses
- Reliance on Single Product (LIVMARLI) for Revenue
- Limited Commercial Infrastructure
- High R&D Expenses
- Competition from Larger Pharmaceutical Companies
Opportunities
- Expansion of LIVMARLI into New Indications
- Acquisition of New Assets
- Partnerships with Larger Pharmaceutical Companies
- Geographic Expansion
Threats
- Clinical Trial Failures
- Regulatory Hurdles
- Competition from New Therapies
- Pricing Pressures
Competitors and Market Share
Key Competitors
- ALNY
- IONS
- GILD
Competitive Landscape
Mirum faces competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its expertise in rare liver diseases.
Major Acquisitions
Albireo Pharma
- Year: 2023
- Acquisition Price (USD millions): 540
- Strategic Rationale: Acquisition to expand the pipeline of products.
Growth Trajectory and Initiatives
Historical Growth: Mirum has experienced revenue growth driven by increased sales of LIVMARLI.
Future Projections: Analysts project continued revenue growth based on expansion of LIVMARLI into new indications and potential approval of pipeline products.
Recent Initiatives: Recent initiatives include clinical trials for new indications of LIVMARLI, the acquisition of other biopharmaceutical businesses.
Summary
Mirum Pharmaceuticals is a biopharmaceutical company focused on rare liver diseases with one approved product, LIVMARLI. The company is growing with continuous R&D to expand to new indications, and also growing through acquisition. They need to watch their burn rate, and market share. They are in a good position to be a market leader in a fast growing niche market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Mirum Pharmaceuticals Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share numbers are estimates based on publicly available data and may not be exact.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mirum Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2019-07-18 | CEO & Director Mr. Christopher Peetz | ||
Sector Healthcare | Industry Biotechnology | Full time employees 355 | Website https://www.mirumpharma.com |
Full time employees 355 | Website https://www.mirumpharma.com | ||
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.